AmCad BioMed Corporation (AmCad), founded in 2008, is one of the pioneers in ultrasound AI diagnostic assessment for multiple clinical indications. We are the company that received the first FDA license for ultrasound CAD solution The company has been publicly traded in Taiwan Stock Exchange since 2015. Our solutions are FDA cleared, CE marked and clinically validated. AmCad's product and pipeline includes AmCAD-UT for thyroid nodules analysis; AmCAD-US for backscattered signals analysis; AmCAD-UO for obstructive sleep apnea detection; AmCAD-CA for cytopathology indication; and iSONO Aid, the state-of-the-art integrated solution aims for real-time detection and diagnosis of various types of cancers.